EVGN_OUT_1 [2025-04-24 04:40:34 -0400] 5839 Bytes | 1535 tokens | Cum: 1535 tkns (19.19% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 4:40 AM on Thu Apr 24, 2025, and I'm firing up the spotlight on EVOGENE (EVGN), moving from $0.9700 to $1.22. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: EVOGENE (EVGN)
IPO: 2013-11-21 (11 Years Ago)
Market Cap: $6,765,009
Shares Outstanding: 6,670,000
Exchange: XNAS
Description: Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.

Here’s a list of headlines for EVOGENE:

Apr-22-25 09:24AM - Why Evogene Ltd. (EVGN) Soared on Monday
Apr-21-25 07:00AM - ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio
Mar-06-25 07:15AM - Evogene Reports Fourth Quarter and Full Year 2024 Financial Results
Mar-06-25 07:15AM 07:00AM - Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025
Feb-20-25 07:00AM - Evogene Schedules Fourth Quarter 2024 Financial Results Release
Feb-13-25 08:00AM - AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease
Nov-21-24 07:30AM - Evogene Reports Third Quarter 2024 Financial Results
Nov-19-24 07:00AM - Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results
Nov-12-24 07:00AM - Lavie Bio Announces Commercial Expansion of Yalos as Seed-Treatment for Soybean, Following Successful Field Trials
Nov-07-24 07:00AM - Evogene Schedules Third Quarter 2024 Financial Results Release
Oct-31-24 08:00AM - Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design
Oct-29-24 08:00AM - Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya
Oct-08-24 07:00AM - Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
Sep-30-24 07:00AM - Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals
Aug-23-24 08:55AM - Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
Aug-22-24 07:00AM - Evogene Reports Second Quarter 2024 Financial Results
Aug-12-24 07:11AM - Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Aug-12-24 07:11AM 07:00AM - Evogene Schedules Second Quarter 2024 Financial Results Release
Jul-31-24 07:00AM - Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil
Jul-23-24 08:48AM - Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
Jul-17-24 08:00AM - ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants
Jul-02-24 07:00AM - Lavie Bio Announces Commercial Expansion of Yalos to Winter Wheat

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-07-19T17:26:33Z - Plant Genotyping Equipment Market Size to Hit 1662.43 - GlobeNewswire
B2 - 2024-07-18T21:02:44Z - Global Agricultural Biotechnology Market Size To Worth USD 268.32 Billion By 2033 | CAGR of 8.27% - GlobeNewswire
B3 - 2024-03-07T14:20:03Z - Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
B4 - 2024-02-28T22:35:04Z - Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
B5 - 2024-02-26T22:10:04Z - Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
B6 - 2024-01-12T17:00:04Z - Here's Why Evogene (EVGN) is a Great Momentum Stock to Buy

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for EVOGENE (EVGN).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

EVGN_OUT_3 [2025-04-24 04:40:34 -0400] 673 Bytes | 190 tokens | Cum: 1727 tkns (21.59% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2237240/evogene-evgn-reports-q4-loss-misses-revenue-estimatesEvogene (EVGN) delivered earnings and revenue surprises of 7.14% and 66.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

EVGN_OUT_5 [2025-04-24 04:40:35 -0400] 827 Bytes | 271 tokens | Cum: 2000 tkns (25.00% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-22T13:24:54Z - Why Evogene Ltd. (EVGN) Soared on Monday...
A2 - 2025-04-22T13:28:43Z - Why Evogene Ltd. (EVGN) Soared on Monday...
A3 - 2025-04-22T11:54:00Z - Pre-market Movers: GELS, HOLO, SHFS, OBIO, FULC....
A4 - 2025-04-21T15:21:57Z - Evogene Stock Soars After ICL Deal To Acquire Lavie Bio, MicroBoost AI - Evogene (NASDAQ:EVGN)...
A5 - 2025-04-21T12:29:15Z - Evogene To Sell Majority Of Lavie Bio To ICL For Undisclosed Terms...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

EVGN_OUT_7 [2025-04-24 04:40:36 -0400] 1181 Bytes | 312 tokens | Cum: 2314 tkns (28.93% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Why Evogene Ltd. (EVGN) Soared on Monday**Date: 2025-04-22Source: {'uri': 'ca.finance.yahoo.com', 'dataType': 'news', 'title': 'Yahoo! Finance'}URL: https://ca.finance.yahoo.com/news/why-evogene-ltd-evgn-soared-132454974.htmlWe recently compiled a list of the 10 Micro-, Small-Cap Companies Lead Monday's Charge. In this article, we are going to take a look at where Evogene Ltd. (NASDAQ:EVGN) stands against the other stocks.

The stock market ended the first trading day of the week in the negative territory, with all major indices recording hefty losses, as investors continued to digest the impact of President Donald Trump's tariff policies and his criticism of the Federal Reserve.

The tech-heavy Nasdaq fell the hardest among the major indices, down 2.55 percent, followed by the Dow Jones at 2.48 percent, and the S&P 500 at 2.36 percent.

Meanwhile, 10 companies bucked a broader mar

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

EVGN_OUT_9 [2025-04-24 04:40:36 -0400] 1181 Bytes | 287 tokens | Cum: 2603 tkns (32.54% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): ket bloodbath, recording strong gains during the day. We have listed the 10 top-performing companies, dominated by micro- to small-cap stocks, and detailed the reasons behind their gains.

To come up with the list, we considered only the stocks with less than $1 billion in market capitalization.

A close-up of a scientist in a lab coat manipulating computational predictive tools.

Evogene Ltd. (NASDAQ:EVGN)

Evogene Ltd. (NASDAQ:EVGN) crawled back to the $1 territory on Monday, jumping 30.93 percent to close at $1.27 apiece following news that it agreed to sell a controlling stake in Lavie Bio Ltd. to ICL, a global specialty minerals and chemicals company.

According to Evogene Ltd. (NASDAQ:EVGN), the acquisition includes its MicroBoost AI for AG platform and is expected to be completed in the second quarter of the year.

Additionally, ICL will gain access to Lavie Bio's assets, includin

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

EVGN_OUT_11 [2025-04-24 04:40:37 -0400] 1181 Bytes | 270 tokens | Cum: 2875 tkns (35.94% of 8k)
==========================================================================

Showing A1 (chunk 3 of 4): g its core team, BDD technology platform, microbial bank, data assets, the majority of its development programs, and its commercial products.

Upon completion, ICL expects to strengthen its position in the ag-biologicals sector.

Lavie Bio is known for its work in the ag-biologicals sector. It develops microbiome-based products aimed at enhancing agricultural productivity and sustainability.

Overall EVGN ranks 9th on our list of Monday's top performers. While we acknowledge the potential of EVGN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than EVGN but that trades at less than 5 times its earnings, check out our r

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

EVGN_OUT_13 [2025-04-24 04:40:38 -0400] 491 Bytes | 128 tokens | Cum: 3005 tkns (37.56% of 8k)
==========================================================================

Showing A1 (chunk 4 of 4): eport about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

EVGN_OUT_15 [2025-04-24 04:40:40 -0400] 238 Bytes | 59 tokens | Cum: 3066 tkns (38.32% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

EVGN_OUT_17 [2025-04-24 04:40:40 -0400] 251 Bytes | 78 tokens | Cum: 3147 tkns (39.34% of 8k)
==========================================================================

You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.

EVGN_OUT_19 [2025-04-24 04:40:48 -0400] 4931 Bytes | 1193 tokens | Cum: 4343 tkns (54.29% of 8k)
==========================================================================

This is our set of metrics for EVOGENE.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-------------------------+
| Volume: 271,332 | Perf Month: -21.58% | Option/Short: No / Yes | Sales Y/Y TTM: 30.69% |
+---------------------+-----------------------+------------------------+-------------------------+
| Avg Volume: 366.18K | Perf Quarter: -39.44% | Short Float: 0.36% | ROE: -331.94% |
+---------------------+-----------------------+------------------------+-------------------------+
| Rel Volume: 0.74 | Index: - | Short Ratio: 0.06 | ROI: - |
+---------------------+-----------------------+------------------------+-------------------------+
| RSI (14): 43.49 | Market Cap: 7.27M | Short Interest: 0.02M | Sales Surprise: -55.56% |
+---------------------+-----------------------+------------------------+-------------------------+
| ATR (14): 0.10 | Shs Outstand: 6.79M | Beta: 1.56 | EPS Surprise: 108.28% |
+---------------------+-----------------------+------------------------+-------------------------+
| SMA20: -4.92% | Shs Float: 6.57M | Sales Q/Q: -52.32% | P/E: - |
+---------------------+-----------------------+------------------------+-------------------------+
| SMA50: -17.08% | Inst Own: 7.10% | Sales past 5Y: - | Earnings: Mar 06 BMO |
+---------------------+-----------------------+------------------------+-------------------------+
| SMA200: -55.00% | Insider Own: 1.56% | Employees: - | |
+---------------------+-----------------------+------------------------+-------------------------+
| Perf Week: 9.55% | Insider Trans: 0.00% | Debt/Eq: - | |
+---------------------+-----------------------+------------------------+-------------------------+

The next section covers any insider trading by EVOGENE officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.09
Average Volume: 1040613.38
30-Day High: 1.375
30-Day Low: 0.97
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of EVOGENE (EVGN).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about EVOGENE.

2) MARKET_SCORE[]
This conversation was initiated because EVGN is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for EVGN.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, EVGN could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect EVGN to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of EVOGENE.

11) ETHICAL_RATING[]
Rate EVOGENE’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of EVOGENE.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

EVGN_IN_21 [2025-04-24 04:40:48 -0400] 126 Bytes | 29 tokens | Cum: 4621 tkns (57.76% of 8k)
==========================================================================

====================================
[2025-04-24 04:40:48] # Analysis Completed
Elapsed Time: 15.61 seconds